Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
ADI team members from across the globe met up in Xi'an China in late October 2024 for the 27th Asia-Pacific Region Conference of Alzheimer’s Disease International and the 2024 Annual Conference of Alzheimer’s Disease Chinese. This blog showcases highlights from the conferences and the ADI Asia Pacific regional meeting.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
ADI is sharing a round-up of the recent activities in the Americas region during this year’s World Alzheimer’s Month. Our member associations in the Americas have showcased their collective strength in the region while making strides in both their dementia awareness-raising efforts as well as their support for those who have been impacted by dementia and their carers.
ADI is sharing a snapshot of the Asia Pacific region’s activities during World Alzheimer’s Month this year. From memory walks, to dementia screenings, to concerts, ADI has been delighted to see such a broad variety of activities dedicated to raising awareness of dementia in the region. With opening words from ADI’s Regional Director for Asia Pacific, we are reporting the multiple actions and efforts that have been taken across the region.
As the World Alzheimer’s Month 2024 campaign draws to close, ADI is proud to report on this year’s achievements from our global community as we united to focus on the urgent message: "Time to act on dementia." With over 81 million global impressions and 4,000 mentions in the media, the campaign brought together dementia associations, advocates, professionals, and carers to raise awareness and reduce stigma to hold events worldwide, including memory walks, exhibitions, presentations, and illuminated landmarks that highlighted the importance of addressing dementia stigma. To all that have taken part, we would like to say thank you for another World Alzheimer’s Month filled with global action.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
ADI’s Diego Aguilar and Nick House attend the Alzheimer's Association International Conference in Philadelphia (USA), delivering key insights, conducting vital meetings and advocating for care in the era of new treatments.
Lecanemab represents the second antibody treatment for Alzheimer’s disease to not be recommended marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease. Donanemab is the…
In under a year, Brazil has made giant leaps in the development of its own National Dementia Plan, culminating in legislation signed by President Luiz Inácio Lula da Silva on 4 June, 2024. ADI revisits the journey that we have shared with our Brazilian member association, Febraz, to help make this plan a reality.